Lifordi's LFD-200 ADC Shows Promise in Treating Autoimmune Disorders
June 11, 2025 — Lifordi Immunotherapeutics presents LFD-200 ADC data showing targeted treatment for autoimmune diseases without systemic toxicity, a potential game-changer in biotech.